| Trial ID: | L7007 |
| Source ID: | NCT00850798
|
| Associated Drug: |
Intensive Glycemic Control
|
| Title: |
The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Intensive glycemic control|DRUG: Conservative glycemic control
|
| Outcome Measures: |
Primary: The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately., Every 6 months and up to 5 years | Secondary: The secondary outcomes are death from any cause, disability from any cause, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more., Every 6 months and upto 5 years
|
| Sponsor/Collaborators: |
Sponsor: Taipei Veterans General Hospital, Taiwan
|
| Gender: |
ALL
|
| Age: |
OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
208
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-02
|
| Completion Date: |
2020-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-07-26
|
| Locations: |
Chen-Hsen Lee, Taipei, 11217, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT00850798
|
